Bosentan Teva 62.5, 125 mg

/ Abic

The treatment in adults is usually started with 62.5 mg twice daily (morning and evening) for the first four weeks. Thereafter, the dose may be increased to 125 mg twice daily, depending on the reaction of the patient.
Children and adolescents: The optimal dosage for children under the age of 12 who suffer from pulmonary arterial hypertension is unknown.

Treatment of pulmonary arterial hypertension (PAH) in patients of WHO functional class II-IV.
Reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease.

Please refer to the patient information leaflet for full details. Please note that patient safety information card is included in each package. The card emphasizes the risks that relate to the use of the product during pregnancy, the risk to the fetus and the contraceptive methods that should be used during treatment with Bosentan Teva and for one additional month after termination of treatment.

Please refer to the patient information leaflet for full details. Please note that patient safety information card  is included in each package. The card emphasizes the risks that relate to the use of the product during pregnancy, the risk to the fetus and the contraceptive methods that should be used during treatment with Bosentan Teva and for one additional month after termination of treatment.

Please refer to the patient information leaflet for full details. Please note that patient safety information card  is included in each package. The card emphasizes the risks that relate to the use of the product during pregnancy, the risk to the fetus and the contraceptive methods that should be used during treatment with Bosentan Teva and for one additional month after termination of treatment.